Article Text

Download PDFPDF
Antinociceptive and Motor-Blocking Action of Epidurally Administered IQB-9302 and Bupivacaine in the Dog
  1. Ignacio A. Gómez de Segura, D.V.M., D.E.C.V.A.,
  2. Isabel Vazquez, M.D. and
  3. Enrique De Miguel, M.D.
  1. From the Department of Experimental Surgery, La Paz University Hospital, Madrid, Spain.
  1. Reprint requests: Ignacio A. Gómez de Segura, D.V.M., D.E.C.V.A., Servicio de Cirugia Experimental, Hospital Universitario La Paz, Castellana 261, 28046 Madrid, Spain. E-mail: ialvarez{at}


Background and Objectives The aim of this study was to compare the antinociceptive and motor-blocking effects of epidurally administered IQB-9302 (C18 H26N2O. HCl) and bupivacaine in the dog.

Methods Twelve adult female Beagle dogs were used. Each animal received 3 concentrations (0.25%, 0.50%, and 0.75%) of either IQB-9302 (n = 6) or bupivacaine (n = 6) by means of a chronic epidural catheter. The nocifensive and motor-blocking status were determined at regular intervals before (baseline) and after drug administration.

Results Epidurally administered IQB-9302 caused a more potent nocifensive and motor-blocking action than bupivacaine. The duration of complete nocifensive block was the longest with IQB-9302, whereas the duration of dermatome nocifensive block was similar for both drugs. The nocifensive to motor block ratio was significantly higher with IQB-9302.

Conclusions IQB-9302 produced an anesthetic action similar to that of bupivacaine, although the former drug induced a slightly more potent nocifensive block. Nocifensive and motor block duration are very similar with IQB-9302, whereas bupivacaine induces a more prolonged motor block without nocifensive block.

  • Local anesthetics
  • IQB-9302
  • Bupivacaine
  • Epidural anesthesia
  • Dog

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Supported by a grant from Inibsa Laboratories, Barcelona, Spain.